After a presentation of interim clinical trial data, shares of Bio-Path Holdings, Inc. (NASDAQ: BPTH) have seen a notable increase. BPTH shares increased by 15.44% to $2.31 as of the most recent market check.
Presentation Of Interim Results
In order to treat acute myeloid leukemia, or AML, Bio-Path (BPTH) revealed preliminary results from their Phase 2 research including prexigebersen, decitabine, and venetoclax. Presented on June 14, 2024, in Madrid, Spain, the data was part of the 2024 European Hematology Association Congress.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prexigebersen has proven to be highly effective in treating two patient groups: those with newly diagnosed AML and those who are resistive to or have relapsed from the disease. These findings were shared by Dr. Jorge Cortes, Director of the Georgia Cancer Center. Both groups surpassed outcomes achieved with frontline therapy.
Detailed Cohort Results
In Cohort 1, which included 31 newly diagnosed patients, 20 were evaluable with a median age of 75 years and adverse-risk or secondary AML (sAML) stemming from myelodysplastic syndromes, chronic myelomonocytic leukemia, or treatment-related AML. Fifteen patients attained complete remission (CR), CRh, or CRi; two patients achieved partial remission (PR), and two maintained stable disease (SD).
Cohort 2 comprised 38 relapsed/refractory patients, of which 23 were evaluable with a median age of 63 years, also presenting adverse-risk or sAML. Twelve patients reached CR/CRi/CRh; one patient achieved PR, eight patients achieved SD, and one experienced treatment failure.
Significance And Future Prospects
The data presented to European oncologists underscores the ongoing need for innovative AML therapies. Despite the study being conducted in the U.S., this presentation aims to educate global oncology leaders on prexigebersen’s potential benefits.
Adverse events among evaluable patients were in line with expectations for decitabine, venetoclax, and AML, with common side effects including fatigue, anemia, and neutropenia, while severe adverse events included febrile neutropenia and sepsis. Encouraged by these interim results, Bio-Path plans to continue enrolling up to 98 and 54 evaluable patients for Cohorts 1 and 2, respectively.
